Gland Pharma Ltd.
NSE: GLAND | BSE: 543245
₹2,869.30
₹202.00
(7.57%)
As on 11-Aug-2026 10:24IST
Market cap
₹43,939 Cr
Revenue (TTM)
₹6,725 Cr
P/E Ratio
38.9
P/B Ratio
4.3
Div. Yield
0.8 %
Quality Score
8/10
Growth Score
7/10
Valuation Score
4/10
Momentum Score
9/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹1,129 Cr
-
ROE
10.6 %
-
ROCE
15 %
-
Industry P/E
38.93
-
EV/EBITDA
19.7
-
Debt to Equity
0
-
Book Value
₹625.1
-
EPS
₹69.6
-
Face value
1
-
Shares outstanding
164,966,661
10 Years Aggregate
CFO
₹6,266.97 Cr
EBITDA
₹10,890.55 Cr
Net Profit
₹7,447.58 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gland Pharma
| 66.6 | 15.7 | 50.7 | 48.3 | 20.0 | -7.3 | -- |
|
BSE Healthcare
| 17.9 | 2.5 | 10.0 | 18.6 | 21.8 | 14.2 | 12.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Gland Pharma
| -4.9 | -6.7 | 22.1 | -59.2 | 63.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
2,869.3 | 43,938.9 | 6,725.3 | 1,128.8 | 19.6 | 11.5 | 38.9 | 4.3 |
| 9.8 | 10.3 | 0.4 | 0.0 | 7.3 | 0.2 | 447.4 | 0.7 | |
| 676.5 | 8,244.4 | 7,229.4 | 210.4 | 4.4 | 11 | 39.2 | 4.1 | |
| 334.3 | 315.8 | 153.1 | 4.3 | 1.4 | 2.3 | 72.8 | 1.7 | |
| 1,849.6 | 17,969.9 | 1,997.4 | 307.0 | 16.7 | 10.6 | 57 | 5.6 | |
| 3.0 | 22.3 | 0.2 | -1.6 | -293.3 | -16.7 | -- | 2.8 |
Shareholding Pattern
View DetailsNews & Analysis
All News
3 min read•By Udhayaprakash
Gland Pharma IPO: Information Analysis
6 min read•By Danish Khanna
About Gland Pharma
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical... ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd. Read more
-
Incorporated
1978
-
Chairman
Srinivas Sadu
-
Managing Director
--
-
Headquarters
Hyderabad, Telangana
-
Website
Looking for more details about Gland Pharma Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Gland Pharma
What is the current share price of Gland Pharma Ltd Today?
The share price of Gland Pharma Ltd is ₹2,869.30 (NSE) and ₹2,867.00 (BSE) as of 11-Aug-2026 10:24 IST. Gland Pharma Ltd has given a return of 19.99% in the last 3 years.
What is the current PB & PE ratio of Gland Pharma Ltd?
The P/E ratio of Gland Pharma Ltd is 38.93 times as on 10-Aug-2026, a 0 premium to its peers’ median range of 38.93 times.
The P/B ratio of Gland Pharma Ltd is 4.26 times as on 10-Aug-2026, a 3 premium to its peers’ median range of 4.12 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2026
|
27.22
|
2.71
|
|
2025
|
37.55
|
2.87
|
|
2024
|
39.27
|
3.48
|
|
2023
|
26.75
|
2.63
|
|
2022
|
44.33
|
7.52
|
What is the 52 Week High and Low of Gland Pharma Ltd?
The 52-week high and low of Gland Pharma Ltd are Rs 2,988.40 and Rs 1,573.60 as of 11-Aug-2026.
What is the market cap of Gland Pharma Ltd?
Gland Pharma Ltd has a market capitalisation of ₹ 43,939 Cr as on 10-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Gland Pharma Ltd?
Before investing in Gland Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.